# Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

> **NCT04511702** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 191 (actual)

## Conditions studied

- Chronic Uncontrolled Gout
- Gout
- Uncontrolled Gout

## Interventions

- **BIOLOGICAL:** Pegloticase with MTX

## Key facts

- **NCT ID:** NCT04511702
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-02
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-03-25
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511702, "Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04511702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*